Newsletter | April 7, 2021

04.07.21 -- Listen Now: Antiviral Conjugates, Peptides, Biopharma Funding Success

Listen Now: Our Latest Podcast Episodes

Check out the latest episodes from The Business of Biotech, Biotech with the Bozenhardts, and Life Science Connect. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters including our podcast series. Don’t forget to subscribe so you never miss an episode!


A CFO's Prescription For Biopharma Success

Life sciences CFO extraordinaire Allan Shaw shares incremental steps to biopharma success and dishes on the mistakes he's seen in his many engagements with new and emerging biotech firms. From capital resource allocation to personnel decision making to preparing for the bubble to burst, listen in as Shaw shares his unfiltered advice.

A Biopharma Pivot Story With Compugen's Dr. Anat Cohen-Dayag
In a remarkably short period of time, Dr. Anat Cohen-Dayag transformed Compugen from a computational biology service provider to a clinical-stage biopharma with multiple cancer immunotherapy candidates. Listen in as she discusses the strategies she deployed to build a biotech on the back of computational science, and her vision for the future of drug discovery. 
Preparing For The Clinic With Amolyt Pharma's Dr. Thierry Abribat
Amolyt Pharma is developing a therapeutic peptide program targeting rare endocrine and metabolic diseases including hypoparathyroidism and acromegaly. Fresh on the heels of its lead candidate's foray into phase 1 clinical trials, we're joined by the company's founder and CEO, Thierry Abribat, Ph.D., for a deep dive into Amolyt Pharma's pre-clinical preparation, including his financing, talent acquisition, and clinical study strategies.
Pioneering Antiviral Conjugates With Cidara's Dr. Jeff Stein

Cidara Therapeutics President and CEO Dr. Jeff Stein joins the Business of Biotech to discuss his career mission to battle microbial organisms and his company's development of a novel approach to producing immunotherapeutic antivirals that couple potent antivirals to a human antibody fragment. We discuss the company's manufacturing approach, which Dr. Stein anticipates yielding a low-cost alternative to standards of care in multiple antiviral indications.



Herman and Erich Bozenhardt have a combined 55 years of bioprocess facilities design and equipment experience, and they’re here to share it all in our fresh Bioprocess with the Bozenhardts podcast series.


Vaccine Advancements And The Future Outlook

Bioprocess Online editor Matt Pillar discusses the current vaccine market, some advancements that have been made, and if its growth is sustainable.